merck p53 stapled peptide patent stapled peptide - cjc-1295-peptide-benefits-and-riskscjc-1295-peptide-benefits-and-risks ALRN-6924 is a cell-penetrating stapled alpha-helical peptide Merck's P53 Stapled Peptide Patent: Advancing Cancer Therapy Through Protein Stabilization

cjc-1295-peptide-mechanism-of-action Merck's pursuit of innovative cancer therapies has prominently featured the development and patenting of stapled peptides, particularly those targeting the p53 tumor suppressor pathway. This strategic focus aims to reactivate the p53 protein, a crucial cell regulator that is frequently inactivated in various cancers, thereby inhibiting tumor growth.WO2016130092A1 -Non-membrane disruptive p53 activating stapled peptides- Google Patents. Non-membrane disruptive p53 activating stapled peptides Download PDF ... The merck p53 stapled peptide patent landscape highlights a sophisticated approach to drug development, where chemical modifications to natural peptides enhance their stability and therapeutic efficacyIDP-410: a Novel Therapeutic Peptide that Alters N-MYC ....

At the core of this research are stapled peptides. These modified peptides are engineered with an artificial cross-link, often referred to as a "staple," that spans across an alpha-helical structure. This structural reinforcement significantly improves the peptide's stability in biological environments, preventing its degradation and prolonging its therapeutic action. This innovation is critical because natural peptides, while potent, are often susceptible to rapid breakdown by cellular proteases.作者：MR Schnorenberg·2023·被引用次数：12—In this work, we hypothesized thatp53reactivation using. ATSP-7041 would prime DLBCL for apoptosis via the BCL-2 family of proteins and ... The "stapling" technique allows for the creation of stapled peptides that mimic the natural interactions of proteins but with enhanced pharmacological propertiesStapled peptide conjugate for degrading MDM2/MDMX ....

A key target for these stapled peptides is the disruption of interactions between p53 and its negative regulators, specifically MDM2 and MDMX. These oncoproteins bind to p53, marking it for degradation and thus neutralizing its tumor-suppressing functions. Stapled p53 peptides are designed to bind to MDM2 and MDMX, displacing p53 and allowing it to become active again.作者：DC Morgan·2025—This diyne-girder-stapled peptidedemonstrated enhanced helicity and nanomolar binding affinity for MDM2, as assessed by fluorescence. This activation can then trigger apoptosis (programmed cell death) in cancer cells or halt their proliferation.作者：M Payton·2017·被引用次数：9—ALRN-6924 is a cell-penetrating stapled alpha-helical peptidedesigned to equipotently disrupt the interaction between the p53 tumor suppressor protein and ... The non-membrane disruptive p53 activating stapled peptides represent a significant advancement, suggesting improved cellular penetration and targeted delivery without compromising cell integrity.

Several patented technologies and research efforts underpin Merck's involvement in this field. For instance, patents like US9527896B2 describe "Stabilized p53 peptides and uses thereof," detailing how these modified peptides interfere with the MDM2 binding, thereby inhibiting p53 destruction. Furthermore, collaborations and patent filings, such as the mention of EP3256484A1 pending, indicate ongoing research and development, potentially involving specific compounds like PM2.

The development of ALRN-6924, a cell-penetrating stapled alpha-helical peptide, exemplifies the clinical progression of this technology. Described as the first-in-class clinical stage stapled peptide, ALRN-6924 is designed to equipotently disrupt the interaction between the p53 tumor suppressor protein and its regulators.Development of an albumin-binding ligand for prolonging ... Clinical trials, including Phase I and Phase II studies, have investigated ALRN-6924 for its efficacy in patients with solid tumors and lymphomas, assessing its potential to restore normal p53-mediated apoptosis activity. This drug also functions as a dual inhibitor of MDMX and MDM2, underscoring the therapeutic strategy of targeting multiple regulatory proteins.

The application of stapled peptides extends beyond direct inhibition of MDM2 and MDMX. Research into non-membrane disruptive and p53 activating stapled peptides also explores methods for effective delivery and targeting. Techniques involving targeted polymersome delivery of a stapled peptide and the use of lipodisks aim to enhance tumor uptake and minimize toxicity to healthy tissues作者：A ZORZI·2017·被引用次数：1—ALRN-6924 is a dual inhibitor of MDM2 and MDMX based on astapled peptidethat interruptsp53suppression and restores normalp53-mediated apoptosis activity in.. This focus on formulation and delivery is critical for translating the promise of stapled peptides into effective clinical treatments.2013年9月26日—Bernal et al.,Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. JAm ChemSoc. Mar. 7, 2007: 129(9):2456-7. Epub Feb ...

The scientific literature also details the underlying design principles for these advanced molecules. For example, the concept of design-rules for stapled peptides with in vivo activity is crucial for optimizing their therapeutic potential.Tumor-Targeted Delivery of the p53-Activating Peptide ... This includes understanding how the "staple" configuration, the choice of amino acids (such as L- or D-amino acids), and overall peptide structure influence binding affinity and cellular activity作者：J Charoenpattarapreeda·2021—This thesis presents two approaches towards the development of novel bioactive molecules with application in cancer therapeutics. 1) Development ofstapled.... The development of these stapled peptides involves a deep understanding of protein-protein interactions and medicinal chemistryStapled peptide conjugate for degrading MDM2/MDMX ....

In summary, Merck's p53 stapled peptide patent portfolio and ongoing research signify a significant commitment to leveraging stapled peptide technology for cancer treatment. By stabilizing key therapeutic molecules like p53 and targeting its regulators, such as MDM2 and MDMX, Merck is paving the way for a new generation of cancer therapies作者：MR Schnorenberg·2023·被引用次数：12—In this work, we hypothesized thatp53reactivation using. ATSP-7041 would prime DLBCL for apoptosis via the BCL-2 family of proteins and .... The continuous innovation in peptide design, delivery mechanisms, and the exploration of compounds like ALRN-6924 underscore the potential of this field to provide life-saving treatments for patients worldwide. The patent landscape in this area, which includes filings like EP3256484A1, is a testament to the robust intellectual property being generated around these groundbreaking therapeutic strategies.